Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Focusing on Synthetic Lethality and Targeting the DNA Damage Response Pathway to Kill Cancer Cells with Oren Gilad Aprea Therapeutics TRANSCRIPT
Download PDFSep 12, 2024
Oren Gilad, President and CEO of Aprea Therapeutics, focused on the DNA damage response pathway, specifically targeting the ATR protein. ATR is a master regulator of DNA replication and is hyperactive in cancer cells, making it a potential Achilles heel for cancer therapy. By inhibiting ATR, cancer cells can be...
Sep 12, 2024
Oren Gilad, President and CEO of Aprea Therapeutics, focused on the DNA damage response pathway, specifically targeting the ATR protein. ATR is a master regulator of DNA replication and is hyperactive in cancer cells, making it a potential Achilles heel for cancer therapy. By inhibiting ATR, cancer cells can be...
Improving Targeting and Penetration of Cancer Therapies for Solid Tumors by Modifying Tumor Microenvironment with David Mazzo Lisata Therapeutics TRANSCRIPT
Download PDFAug 23, 2024
David Mazzo, President and CEO of Lisata Therapeutics, has a lead program focused on metastatic pancreatic ductal adenocarcinoma. The Lisata CendR Platform and drug certepetide efficiently augment the effects of chemotherapy and immunotherapies in the tumor microenvironment. Based on early findings, the future of cancer...
Aug 23, 2024
David Mazzo, President and CEO of Lisata Therapeutics, has a lead program focused on metastatic pancreatic ductal adenocarcinoma. The Lisata CendR Platform and drug certepetide efficiently augment the effects of chemotherapy and immunotherapies in the tumor microenvironment. Based on early findings, the future of cancer...
Antibody Drug Conjugate Targets Claudin 18.2 to Treat Gastric Cancer with Joe Ferra Elevation Oncology TRANSCRIPT
Download PDFJul 16, 2024
Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly...